Tags

Type your tag names separated by a space and hit enter

Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety.
J Med Virol. 2022 06; 94(6):2369-2375.JM

Abstract

At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies.

Authors+Show Affiliations

Department of Nephrology, National Clinical Research Center for Child Health, National Children's Regional Medical Center, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.Department of Nephrology, National Clinical Research Center for Child Health, National Children's Regional Medical Center, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.Department of Clinical Laboratory, National Clinical Research Center for Child Health, National Children's Regional Medical Center, The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

35028946

Citation

Meng, Hanyan, et al. "Booster Vaccination Strategy: Necessity, Immunization Objectives, Immunization Strategy, and Safety." Journal of Medical Virology, vol. 94, no. 6, 2022, pp. 2369-2375.
Meng H, Mao J, Ye Q. Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. J Med Virol. 2022;94(6):2369-2375.
Meng, H., Mao, J., & Ye, Q. (2022). Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. Journal of Medical Virology, 94(6), 2369-2375. https://doi.org/10.1002/jmv.27590
Meng H, Mao J, Ye Q. Booster Vaccination Strategy: Necessity, Immunization Objectives, Immunization Strategy, and Safety. J Med Virol. 2022;94(6):2369-2375. PubMed PMID: 35028946.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. AU - Meng,Hanyan, AU - Mao,Jianhua, AU - Ye,Qing, Y1 - 2022/01/19/ PY - 2022/01/09/revised PY - 2021/12/22/received PY - 2022/01/10/accepted PY - 2022/1/15/pubmed PY - 2022/4/20/medline PY - 2022/1/14/entrez KW - COVID-19 KW - SARS-CoV-2 KW - booster vaccination KW - heterologous vaccination KW - vaccine SP - 2369 EP - 2375 JF - Journal of medical virology JO - J Med Virol VL - 94 IS - 6 N2 - At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies. SN - 1096-9071 UR - https://www.unboundmedicine.com/medline/citation/35028946/Booster_vaccination_strategy:_Necessity_immunization_objectives_immunization_strategy_and_safety_ L2 - https://doi.org/10.1002/jmv.27590 DB - PRIME DP - Unbound Medicine ER -